Drug intelligence / Profile preview

morphine sulfate ER + oxycodone ER + oxymorphone ER

Development stage
Unknown
Lead developer
Mallinckrodt
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination of three extended-release opioid analgesics: morphine sulfate, oxycodone, and oxymorphone. Each drug acts primarily as an agonist at the mu-opioid receptor, producing analgesia by inhibiting pain signaling in the central nervous system. Morphine and its derivatives are considered prototypical opioids; oxycodone also has activity at kappa and delta opioid receptors, while oxymorphone is a potent mu-opioid receptor agonist with higher lipophilicity than morphine, allowing for more efficient blood-brain barrier penetration[2][5][6]. All three drugs are indicated for the management of severe pain requiring continuous, long-term opioid treatment when alternative options are inadequate[2][3][4]. These agents have similar adverse effect profiles typical of opioids (e.g., constipation, nausea/vomiting, sedation)[2]. Extended-release formulations provide sustained plasma concentrations to allow 12-hour or longer dosing intervals.

Brand names
MS ContinKadianOxyContinXtampza EROpana ER
Other names
extended-release morphine sulfateextended-release oxycodoneextended-release oxymorphone
02

Targets

KOR (Kappa opioid receptor)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on morphine sulfate ER + oxycodone ER + oxymorphone ER.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on morphine sulfate ER + oxycodone ER + oxymorphone ER.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call